Revelation Biosciences grants CEO and CFO restricted stock with market-cap vesting

REVELATION BIOSCIENCES, INC.

CEO James Rolke granted 208,076 restricted shares; CFO Chester Zygmont granted 208,073 shares, effective Aug 17, 2026.
Awards vest in four 25% tranches upon 20-day market caps of $30M, $60M, $90M, $120M, or by 2nd/4th anniversaries.
Full vesting on change in control; accelerated on death, termination without cause, or for good reason.
Unvested shares forfeited on termination for cause, disability, or retirement; dividends held with same restrictions.
Grants made under Amended and Restated 2021 Equity Incentive Plan; form of award agreement filed as Exhibit 10.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.